Targeting Anti-TGF-β Therapy to Fibrotic Kidneys with a Dual Specificity Antibody Approach.
Targeting Anti-TGF-β Therapy to Fibrotic Kidneys with a Dual Specificity Antibody Approach.
S. McGaraughty,R. Davis-Taber,14 Authors,S. E. Lacy
2017 · DOI: 10.1681/ASN.2017010013
Journal of the American Society of Nephrology · 48 Citations
TLDR
Overall, systemic delivery of a bispecific molecule targeting an extracellular matrix protein and delivering a TGF-β mAb resulted in a relatively focal uptake in the fibrotic kidney and reduced renal fibrosis.